The calibration of a semi-quantitative approach to fish stock assessment in the North West Region of the NRA

(1) A total of 45 sites was sampled, each being fished using the semi-quantitative and quantitative techniques. (2) A significant relationship existed between the semi-quantitative and Quantitative results for all age groups of salmonids (R2 83.4% to 96.1%, p < 0.0001). (3) The results from each site were categorised according to an existing classification system for quantitative and semi-quantitative data. The semi-quantitative component of this system was modified using the results of this investigation. The degree of error associated with sites classified semi-quantitatively was found to be slightly less when using the modified system for 0+ salmon, > 0+ salmon and 0+ trout, ranging from 10.5% to 30%. (4) Insufficient data points were available for the analysis of coarse fish data

NRA North west salmonid microtagging programme 1987-1994

The microtagging programme began in 1987 using hatchery reared salmon originating from the rivers Caldew and Hodder and subsequently included the Lune (1988) and Ribble (1989). Microtagging of sea trout began in 1991 for the Lune and in 1993 for the Hodder. The report explores the NRA North west salmonid microtagging programme looking at methods, results and recommendations. The report provides salmon microtagging data and returns from 1987 to 1994

Effects of financial incentives on motivating physical activity among older adults: Results from a discrete choice experiment

10.1186/1471-2458-14-141BMC Public Health141

Aluminosilicates and yeast-based mycotoxin binders: Their ameliorated effects on growth, immunity and serum chemistry in broilers fed aflatoxin and ochratoxin

The aim of this study was to evaluate the effects of commercial toxin binders on growth performance, organ morphology, immunity and serum biochemistry in broilers. Dietary treatments consisted of the negative control (NC): experimental diet with aflatoxin B1 &lt;20 parts per billion (ppb), ochratoxin A (OTA) &lt;5 ppb; control (C) experimental diet without toxin binder; Z1: toxin binder 1 g/kg of zeta plus; Z2: toxin binder 2 g/kg of zeta plus; TX1: toxin binder 1 g/kg of Toxfin Dry; and TX2: toxin binder 2 g/kg of Toxfin Dry). Except for NC, all diets contained 57 ppb aflatoxin B1 and 23 ppb ochratoxin A. Feed intake was higher in the TX1, TX2, NC, Z2 and Z1 treatments than in the control. Weight gain was higher in Z2, TX2, Z1, TX1 and NC than in C. Feed conversion ratio (FCR) was poor in C. The control had the highest liver weight, though the weights of the spleen, kidneys and hearts of the birds were similar in all treatments. Gizzard weight, thymus weight, and bursa of Fabricius were lowest in C. The weight of the pancreas was similar among treatments. The antibody titres against new castle disease were higher in treatments Z2, Z1, TX2, TX1 and NC than in C. Urea and creatinine concentrations, and aspartate aminotransferase activity in serum were similar among treatments, whereas the serum alanine transaminase activity was higher in C than in Z1, TX1, TX2, Z2 and NC. It was concluded that growth rate, FCR and immunity indices were improved in broilers fed toxin binder. At lower levels of mycotoxin in feed, 1 g/kg of toxin binder (clay based or yeast based) was sufficient to ameliorate the adverse effects of aflatoxin B1 and OTA, whereas at higher levels of mycotoxins, supplementation of toxin binder should be increased.Keywords: alanine aminotransferase, aspartate aminotransferase, carcass characteristics, growth performance, toxin binders, urea, creatinin

Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia

Biological, physical and clinical aspects of cancer treatment with ionising radiatio

Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth

Prostate cancer is the most common cancer in men and it is estimated that over 350,000 men worldwide die of prostate cancer every year. There remains an unmet clinical need to improve how clinically significant prostate cancer is diagnosed and develop new treatments for advanced disease. Aberrant glycosylation is a hallmark of cancer implicated in tumour growth, metastasis, and immune evasion. One of the key drivers of aberrant glycosylation is the dysregulated expression of glycosylation enzymes within the cancer cell. Here, we demonstrate using multiple independent clinical cohorts that the glycosyltransferase enzyme GALNT7 is upregulated in prostate cancer tissue. We show GALNT7 can identify men with prostate cancer, using urine and blood samples, with improved diagnostic accuracy than serum PSA alone. We also show that GALNT7 levels remain high in progression to castrate-resistant disease, and using in vitro and in vivo models, reveal that GALNT7 promotes prostate tumour growth. Mechanistically, GALNT7 can modify O-glycosylation in prostate cancer cells and correlates with cell cycle and immune signalling pathways. Our study provides a new biomarker to aid the diagnosis of clinically significant disease and cements GALNT7-mediated O-glycosylation as an important driver of prostate cancer progression